Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced it will release its 2024 full year and fourth quarter financial results on Tuesday, February 25, 2025, after U.S. market close. The company will host a live audio webcast at 4:30 p.m. ET to discuss the results and provide business updates.
The webcast will be accessible through Jazz Pharmaceuticals' Investor Relations website, with dial-in numbers available for U.S. (+1 800 715 9871) and Ireland (+353 1800 943 926) participants. Interested parties are advised to register 15 minutes before the scheduled webcast.
Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for serious diseases, with a portfolio including therapies for sleep disorders, epilepsy, and cancer treatments.
Jazz Pharmaceuticals (Nasdaq: JAZZ) ha annunciato che pubblicherà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 martedì 25 febbraio 2025, dopo la chiusura del mercato statunitense. L'azienda ospiterà una diretta audio in webcast alle 16:30 ET per discutere i risultati e fornire aggiornamenti aziendali.
Il webcast sarà accessibile tramite il sito web delle Relazioni con gli Investitori di Jazz Pharmaceuticals, con numeri di accesso disponibili per i partecipanti statunitensi (+1 800 715 9871) e irlandesi (+353 1800 943 926). Si consiglia alle parti interessate di registrarsi 15 minuti prima del webcast programmato.
Jazz Pharmaceuticals è un'azienda biopharma globale focalizzata nello sviluppo di farmaci che cambiano la vita per malattie gravi, con un portfolio che include terapie per disturbi del sonno, epilessia e trattamenti per il cancro.
Jazz Pharmaceuticals (Nasdaq: JAZZ) ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 el martes 25 de febrero de 2025, después del cierre del mercado en EE.UU. La compañía ofrecerá una transmisión en vivo por audio a las 4:30 p.m. ET para discutir los resultados y proporcionar actualizaciones comerciales.
La transmisión será accesible a través del sitio web de Relaciones con Inversores de Jazz Pharmaceuticals, con números de marcación disponibles para los participantes de EE.UU. (+1 800 715 9871) e Irlanda (+353 1800 943 926). Se recomienda a las partes interesadas registrarse 15 minutos antes del webcast programado.
Jazz Pharmaceuticals es una empresa biofarmacéutica global centrada en desarrollar medicamentos que cambian la vida para enfermedades graves, con un portafolio que incluye terapias para trastornos del sueño, epilepsia y tratamientos oncológicos.
재즈 제약 (Nasdaq: JAZZ)는 2024년 전체 및 4분기 재무 결과를 2025년 2월 25일 화요일, 미국 시장 마감 후 발표할 것이라고 발표했습니다. 이 회사는 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 동부 표준시 기준 오후 4시 30분에 라이브 오디오 웹캐스트를 진행할 것입니다.
웹캐스트는 재즈 제약의 투자자 관계 웹사이트를 통해 접속할 수 있으며, 미국 (+1 800 715 9871) 및 아일랜드 (+353 1800 943 926) 참가자를 위한 전화 접속 번호도 제공됩니다. 관심이 있는 당사자는 예정된 웹캐스트 15분 전에 등록할 것을 권장합니다.
재즈 제약은 심각한 질병에 대한 생명을 변화시키는 약물을 개발하는 데 주력하는 글로벌 바이오 제약 회사로, 수면 장애, 간질 및 암 치료를 위한 치료제를 포함하는 포트폴리오를 보유하고 있습니다.
Jazz Pharmaceuticals (Nasdaq: JAZZ) a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année 2024 le mardi 25 février 2025, après la clôture du marché américain. L'entreprise organisera un webinaire audio en direct à 16h30 ET pour discuter des résultats et fournir des mises à jour commerciales.
Le webinaire sera accessible via le site des relations investisseurs de Jazz Pharmaceuticals, avec des numéros de connexion disponibles pour les participants des États-Unis (+1 800 715 9871) et d'Irlande (+353 1800 943 926). Les parties intéressées sont conseillées de s'inscrire 15 minutes avant le webinaire prévu.
Jazz Pharmaceuticals est une entreprise biopharmaceutique mondiale axée sur le développement de médicaments qui changent la vie pour des maladies graves, avec un portefeuille incluant des thérapies pour les troubles du sommeil, l'épilepsie et les traitements contre le cancer.
Jazz Pharmaceuticals (Nasdaq: JAZZ) hat bekannt gegeben, dass sie ihre Finanzergebnisse für das Gesamtjahr und das vierte Quartal 2024 am Dienstag, den 25. Februar 2025, nach Börsenschluss in den USA veröffentlichen wird. Das Unternehmen wird um 16:30 Uhr ET ein Live-Audio-Webcast veranstalten, um die Ergebnisse zu besprechen und Unternehmens-Updates bereitzustellen.
Der Webcast wird über die Investor-Relations-Website von Jazz Pharmaceuticals zugänglich sein, mit Einwahlnummern für Teilnehmer aus den USA (+1 800 715 9871) und Irland (+353 1800 943 926). Interessierten Parteien wird geraten, sich 15 Minuten vor dem geplanten Webcast zu registrieren.
Jazz Pharmaceuticals ist ein globales Biopharma-Unternehmen, das sich auf die Entwicklung lebensverändernder Medikamente für schwerwiegende Erkrankungen konzentriert und ein Portfolio mit Therapien für Schlafstörungen, Epilepsie und Krebsbehandlungen anbietet.
- None.
- None.
Audio webcast/conference call:
Ireland Dial-In Number: +353 1800 943 926
Additional global dial-in numbers are available here.
Passcode: 5080203
Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Contacts:
Investors:
Jeff Macdonald
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2024-full-year-and-fourth-quarter-financial-results-on-february-25-2025-302373933.html
SOURCE Jazz Pharmaceuticals plc
FAQ
When will Jazz Pharmaceuticals (JAZZ) report its Q4 2024 earnings?
How can investors access JAZZ's Q4 2024 earnings call?
What is the passcode for JAZZ's Q4 2024 earnings call?
Will there be a replay available for JAZZ's Q4 2024 earnings webcast?
